BioSpace News Archive

As the weather cools down, let’s look back at this summer’s most popular career advice on BioSpace.

Regeneus Ltd today reported that it has received $2.4m from the Australian Government’s Research and Development tax incentive program for activities conducted during the financial year 2018.

Polyphor and Novo Holdings A / S announced today that got Polyphor CHF 6.8 million in new capital from Novo REPAIR Impact Fund to promote the development of novel antibiotics directed against proteins of the outer cell membrane.

The first stage of the Phase IIa study with YELIVA® for advanced cholangiocarcinoma (bile duct cancer), a highly lethal malignancy, achieved its pre-specified efficacy goal, and the study can therefore continue to its second stage, enrolling the full cohort of 39 evaluable patients who previous received other treatments

BioCryst Pharmaceuticals, Inc. today announced that the Centers for Disease Control and Prevention (CDC) has awarded BioCryst a $34.7 million contract for the procurement of up to 50,000 doses of BioCryst’s approved antiviral influenza therapy, RAPIVAB® (peramivir injection) over a five-year period.

Dr Wan Yue joins international CIFAR research programme.

The predominant theory behind the causes of Alzheimer’s disease is related to the accumulation of a type of protein in the brain of patients called beta-amyloid. This theory has come under criticism lately, largely due to the lack of success of a number of drugs that prevent or clear beta-amyloid in late-stage clinical trials.

Amicus Therapeutics, headquartered in Cranbury, New Jersey, held a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding its regulatory path for AT-GAA for Pompe Disease. The company released its plans for the drug.

EpicGenetics and Massachusetts General Hospital (MGH) are launching a Phase II clinical trial to test a tuberculosis vaccine, BCG, as a potential treatment for fibromyalgia.

Azeria Therapeutics Limited today announced that it has successfully raised £4 million in Series A fundraising from the £70 million CRT Pioneer Fund, managed by Sixth Element Capital LLP (6EC), a UK based fund manager.